Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CCCC | Common Stock | Options Exercise | +12.5K | +5.82% | 227K | Nov 7, 2024 | Direct | F1 | ||
transaction | CCCC | Common Stock | Tax liability | -$33.5K | -5.55K | -2.44% | $6.04 | 222K | Nov 7, 2024 | Direct | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CCCC | Performance Restricted Stock Units | Options Exercise | $0 | -12.5K | -26.32% | $0.00 | 35K | Nov 7, 2024 | Common Stock | 12.5K | Direct | F1 |
Id | Content |
---|---|
F1 | Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. |
F2 | Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. |